Business
AstraZeneca, Daiichi Sankyo in $6B oncology deal – MarketWatch
AstraZeneca PLC said Monday that it has entered into an oncology collaboration with Daiichi Sankyo Co. worth up to $6 billion that it said could redefine treatment standards in lung, breast and multiple other cancers.
The British pharmaceutical giant said it and Daiichi Sankyo will jointly develop and commercialize a new antibody drug conjugate, DS-1062, world-wide, except in Japan. The drug is currently in development, AstraZeneca said.
Under the collaboration, AstraZeneca will pay Daiichi Sa…
-
Noosa News22 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
Noosa News23 hours agoThe Best Things to Do in Brisbane This New Year’s Eve
-
General22 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
General14 hours agoMan refused bail charged with depicting Adolf Hitler and Nazi symbols on boat